Suppr超能文献

分娩途径调节间充质干细胞治疗心肌梗死的疗效:一项临床前研究和临床试验的荟萃分析。

Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials.

作者信息

Kanelidis Anthony J, Premer Courtney, Lopez Juan, Balkan Wayne, Hare Joshua M

机构信息

From the Interdisciplinary Stem Cell Institute (A.J.K., C.P., W.B., J.M.H.), Department of Molecular and Cellular Pharmacology (C.P.), and Department of Medicine (W.B., J.M.H.), University of Miami Miller School of Medicine, FL; and Florida International University Herbert Wertheim College of Medicine, Miami (J.L.).

出版信息

Circ Res. 2017 Mar 31;120(7):1139-1150. doi: 10.1161/CIRCRESAHA.116.309819. Epub 2016 Dec 28.

Abstract

RATIONALE

Accumulating data support a therapeutic role for mesenchymal stem cell (MSC) therapy; however, there is no consensus on the optimal route of delivery.

OBJECTIVE

We tested the hypothesis that the route of MSC delivery influences the reduction in infarct size and improvement in left ventricular ejection fraction (LVEF).

METHODS AND RESULTS

We performed a meta-analysis investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n=1165 mouse, rat, swine) which revealed a reduction in infarct size and improvement of LVEF in all animal models. Route of delivery was analyzed in AMI swine studies and clinical trials (6 clinical trials; n=334 patients). In AMI swine studies, transendocardial stem cell injection reduced infarct size (n=49, 9.4% reduction; 95% confidence interval, -15.9 to -3.0), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicated no improvement. Similarly, transendocardial stem cell injection improved LVEF (n=65, 9.1% increase; 95% confidence interval, 3.7 to 14.5), as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement. In humans, changes of LVEF paralleled these results, with transendocardial stem cell injection improving LVEF (n=46, 7.0% increase; 95% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement.

CONCLUSIONS

MSC therapy improves cardiac function in animal models of both AMI and chronic ischemic cardiomyopathy. The route of delivery seems to play a role in modulating the efficacy of MSC therapy in AMI swine studies and clinical trials, suggesting the superiority of transendocardial stem cell injection because of its reduction in infarct size and improvement of LVEF, which has important implications for the design of future studies.

摘要

理论依据

越来越多的数据支持间充质干细胞(MSC)治疗的治疗作用;然而,关于最佳给药途径尚无共识。

目的

我们检验了以下假设,即MSC给药途径会影响梗死面积的缩小和左心室射血分数(LVEF)的改善。

方法与结果

我们进行了一项荟萃分析,研究MSC治疗在急性心肌梗死(AMI)和慢性缺血性心肌病临床前研究中的效果(58项研究;n = 1165只小鼠、大鼠、猪),结果显示在所有动物模型中梗死面积均减小,LVEF均改善。在AMI猪研究和临床试验(6项临床试验;n = 334例患者)中分析了给药途径。在AMI猪研究中,经心内膜干细胞注射可减小梗死面积(n = 49,减小9.4%;95%置信区间,-15.9至-3.0),而直接心肌内注射、静脉输注和冠状动脉内输注均未显示有改善。同样,经心内膜干细胞注射可改善LVEF(n = 65,增加9.1%;95%置信区间,3.7至14.5),直接心肌内注射和静脉输注也如此,而冠状动脉内输注未显示有改善。在人类中,LVEF的变化与这些结果相似,经心内膜干细胞注射可改善LVEF(n = 46,增加7.0%;95%置信区间,2.7至11.3),静脉输注也如此,但冠状动脉内输注再次未显示有改善。

结论

MSC治疗可改善AMI和慢性缺血性心肌病动物模型的心脏功能。给药途径似乎在调节AMI猪研究和临床试验中MSC治疗的疗效方面发挥作用,提示经心内膜干细胞注射具有优越性,因为其可减小梗死面积并改善LVEF,这对未来研究的设计具有重要意义。

相似文献

引用本文的文献

7
Application of Pro-angiogenic Biomaterials in Myocardial Infarction.促血管生成生物材料在心肌梗死中的应用
ACS Omega. 2024 Aug 27;9(36):37505-37529. doi: 10.1021/acsomega.4c04682. eCollection 2024 Sep 10.

本文引用的文献

8
Mesenchymal stem cell therapy for cardiac repair.用于心脏修复的间充质干细胞疗法。
Curr Treat Options Cardiovasc Med. 2014 Jul;16(7):323. doi: 10.1007/s11936-014-0323-4.
9
Mesenchymal stem cell delivery routes and fate.间充质干细胞的递送途径与命运
Int J Stem Cells. 2008 Nov;1(1):1-7. doi: 10.15283/ijsc.2008.1.1.1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验